Chongqing Xishan Science & Technology Co (688576) Fair Value & Analysis
Healthcare · CN · Market cap 3.1B CNY
Fair value as of: Jun 24, 2026
Analysis
Chongqing Xishan Science & Technology Co (688576) currently trades at ¥44.54, while our model-based Fair Value estimate is ¥22.82 — implying the stock looks roughly 48.8% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
About the company
Chongqing Xishan Science & Technology Co., Ltd. engages in the research and development, manufacturing, sale, and service of digital minimally invasive surgical equipment and medical consumables in China and internationally. The company offers powered surgical instruments, such as micromotor, handpiece, attachment, shaver, bur, saw blade, and perforator; vacuum-assisted breast biopsy, including control module, handpiece, probe, and canister. It also provides UHD endocsopy systems comprising camera control unit, camera head, light source unit, LCD monitor, transforaminal endoscope, arthroscope, sinoscope, laparoscope, and trolley; ultrasonic bone scalpel systems; RF/HF electrosurgical unit and surgical electrode; and plasma electrosurgical unit and plasma surgical electrode. The company was founded in 1999 and is headquartered in Chongqing, China.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Chongqing Xishan Science & Technology Co (688576) undervalued?
What is the fair value of 688576?
What is the quality score of 688576?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.